OCGN logo

OCGN
Ocugen Inc

154,442
Mkt Cap
$586.94M
Volume
662,819.00
52W High
$2.73
52W Low
$0.57
PE Ratio
-7.93
OCGN Fundamentals
Price
$1.79
Prev Close
$1.79
Open
$1.81
50D MA
$1.76
Beta
1.61
Avg. Volume
12.46M
EPS (Annual)
-$0.226
P/B
-45.96
Rev/Employee
$38,043.10
$419.80
Loading...
Loading...
News
all
press releases
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell
Wall Street Zen downgraded shares of Ocugen from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·3d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN
Hennion & Walsh Asset Management Inc. bought a new position in shares of Ocugen, Inc. (NASDAQ:OCGN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,005,981 shares of the company's stock, valued at approximately $1,358,000. Hen...
MarketBeat·3d ago
News Placeholder
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.
Zacks·4d ago
News Placeholder
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·5d ago
News Placeholder
What is Noble Financial's Estimate for Ocugen Q3 Earnings?
Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Investment analysts at Noble Financial lowered their Q3 2026 earnings per share estimates for shares of Ocugen in a research report issued on Wednesday...
MarketBeat·10d ago
News Placeholder
HC Wainwright Issues Positive Forecast for Ocugen Earnings
Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for shares of Ocugen in a research report issued to clients and investors...
MarketBeat·10d ago
News Placeholder
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital
Chardan Capital restated a "buy" rating and set a $7.00 price objective on shares of Ocugen in a report on Wednesday...
MarketBeat·12d ago
News Placeholder
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Zacks·12d ago
News Placeholder
HC Wainwright Increases Ocugen (NASDAQ:OCGN) Price Target to $10.00
HC Wainwright upped their target price on shares of Ocugen from $7.00 to $10.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·12d ago
<
1
2
...
>

Latest OCGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.